These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24097085)

  • 1. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
    Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
    Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population.
    Rogers JE; Cumpston A; Newton M; Craig M
    Transpl Infect Dis; 2011 Oct; 13(5):480-4. PubMed ID: 21615848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella Zoster Virus Infection in Children with Autologous Hematopoietic Cell Transplantation: A Retrospective, Single-Center Study in Korea.
    Kang JM; Kim JM; Lee JW; Yoo KH; Sung KW; Koo HH; Kim YJ
    Biol Blood Marrow Transplant; 2020 May; 26(5):965-971. PubMed ID: 31962166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
    Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.
    Onozawa M; Hashino S; Haseyama Y; Hirayama Y; Iizuka S; Ishida T; Kaneda M; Kobayashi H; Kobayashi R; Koda K; Kurosawa M; Masauji N; Matsunaga T; Mori A; Mukai M; Nishio M; Noto S; Ota S; Sakai H; Suzuki N; Takahashi T; Tanaka J; Torimoto Y; Yoshida M; Fukuhara T
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):724-9. PubMed ID: 19450757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.
    Han SB; Kim SK; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH
    Medicine (Baltimore); 2017 Apr; 96(14):e6546. PubMed ID: 28383421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
    Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
    Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting risk factors for varicella zoster virus infection and postherpetic neuralgia after hematopoietic cell transplantation using ordered logistic regression analysis.
    Kanbayashi Y; Matsumoto Y; Kuroda J; Kobayashi T; Horiike S; Hosokawa T; Taniwaki M
    Ann Hematol; 2017 Feb; 96(2):311-315. PubMed ID: 27896415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Acyclovir Prophylaxis for
    Fei N; Shah N; Cumpston A; Wen S; Ross KG; Craig M; Kanate AS
    Clin Hematol Int; 2019 Jun; 1(2):101-104. PubMed ID: 34595417
    [No Abstract]   [Full Text] [Related]  

  • 12. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
    Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of VZV infection in immunosuppressed patients using antiviral agents.
    Boeckh M
    Herpes; 2006 Nov; 13(3):60-5. PubMed ID: 17147908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.
    Swaika A; Paulus A; Miller KC; Sher T; Almyroudis NG; Ball D; Wood M; Masood A; Lee K; Chanan-Khan AA
    J Support Oncol; 2012; 10(4):155-9. PubMed ID: 22222250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varicella-Zoster Virus Reactivation After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation, Single-Center Experience of Acyclovir Prophylaxis.
    Arıcı G; Ince E; Ince E; Ileri T; Ciftci E; Dogu F; Ozdemir H; Cakmakli HF; Ertem M
    Pediatr Transplant; 2024 Aug; 28(5):e14819. PubMed ID: 38924278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
    Vermont CL; Jol-van der Zijde EC; Hissink Muller P; Ball LM; Bredius RG; Vossen AC; Lankester AC
    Transpl Infect Dis; 2014 Apr; 16(2):188-94. PubMed ID: 24438482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
    Kim DH; Messner H; Minden M; Gupta V; Kuruvilla J; Wright J; Lipton J
    Transpl Infect Dis; 2008 Apr; 10(2):90-8. PubMed ID: 17605742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
    Wada-Shimosato Y; Tanoshima R; Hiratoko K; Takeuchi M; Tsujimoto SI; Shiba N; Ito S; Yamanaka T; Ito S
    Transpl Infect Dis; 2019 Jun; 21(3):e13061. PubMed ID: 30756465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
    Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
    Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.